Similar Papers

Paper Title
Journal
Date
Author
Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)
Robert Bermel ... Jens Wuerfel
Neurology | VOL. 100
Robert Bermel, et. al.Robert Bermel ... Jens Wuerfel
25 Apr 2023
An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial (S31.006)
Evanthia Bernitsas ... Richard Sater
Neurology | VOL. 100
Evanthia Bernitsas, et. al.Evanthia Bernitsas ... Richard Sater
25 Apr 2023
Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)
Joao Cerqueira ... Eva Havrdova
Neurology | VOL. 100
Joao Cerqueira, et. al.Joao Cerqueira ... Eva Havrdova
25 Apr 2023
NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)
Sarah Harris ... Ludwig Kappos
Neurology | VOL. 100
Sarah Harris, et. al.Sarah Harris ... Ludwig Kappos
25 Apr 2023
View more papers

More From: Neurology

Paper Title
Journal
Date
Author
Reader Response: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Calixto Machado
Neurology | VOL. -
Calixto MachadoCalixto Machado
28 Jan 2025
Brain Hypertrophy in Patients With Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis and Its Clinical Correlates
Richard Zubal ... Marian Galovic
Neurology | VOL. 104
Richard Zubal, et. al.Richard Zubal ... Marian Galovic
28 Jan 2025
Reader Response: Wall-Eyed Bilateral Internuclear Ophthalmoplegia Variant Syndrome Caused by Isolated Left Thalamic Infarction.
Eric R Eggenberger
Neurology | VOL. 104
Eric R EggenbergerEric R Eggenberger
28 Jan 2025
Editors' Note: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Aravind Ganesh ... Steven L Galetta
Neurology | VOL. -
Aravind Ganesh, et. al.Aravind Ganesh ... Steven L Galetta
28 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.